Alexander A Cohen, Jennifer R Keeffe, Ariën Schiepers, Sandra E Dross, Allison J Greaney, Annie V Rorick, Han Gao, Priyanthi N P Gnanapragasam, Chengcheng Fan, Anthony P West, Arlene I Ramsingh, Jesse H Erasmus, Janice D Pata, Hiromi Muramatsu, Norbert Pardi, Paulo J C Lin, Scott Baxter, Rita Cruz, Martina Quintanar-Audelo, Ellis Robb, Cristina Serrano-Amatriain, Leonardo Magneschi, Ian G Fotheringham, Deborah H Fuller, Gabriel D Victora, Pamela J Bjorkman
Immunization with mosaic-8b [60-mer nanoparticles presenting 8 SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs)] elicits more broadly cross-reactive antibodies than homotypic SARS-CoV-2 RBD-only nanoparticles and protects against sarbecoviruses. To investigate original antigenic sin (OAS) effects on mosaic-8b efficacy, we evaluated effects of prior COVID-19 vaccinations in non-human primates and mice on sarbecovirus response breadths elicited by mosaic-8b, admix-8b (8 homotypics), and homotypic SARS-CoV-2, finding greatest cross-reactivity for mosaic-8b...
February 9, 2024: bioRxiv